Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy

Darren King, Kai Wu, Qianyi Ma, Josephine Dubois, Xianing Zheng, Mohamed Rizk, Kerby Shedden, Malathi Kandarpa, Dan Boyer, Karan Bedi, Jun Li, Sami N. Malek

Blood (2024) 144 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2024-197941

Published: 2024

Journal Articles

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Erin M Kropp, Sho Matono, Aaron Robida, Malathi Kandarpa, Olivia Wang, Andrew Alt, Moshe Talpaz, Matthew Pianko, Qing Li

Blood (2024) 144 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2024-203713

Published: 2024

Journal Articles

Examining Ras/MAP Kinase Signaling in Primary Myelofibrosis May Yield Insight into the Mechanisms of JAK Inhibitor Resistance and Provide New Therapeutic Targets

Samuel B Reynolds, Malathi Kandarpa, Mark Ribick, Moshe Talpaz, Qing Li

Blood (2024) 144 (Supplement 1): 6568.

https://doi.org/10.1182/blood-2024-199399

Published: 2024

Journal Articles

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Henry Dumke, Kellen Fitzpatrick, Tycel Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox, Dahlia Sano, Malathi Kandarpa, Avery Polk, Benjamin L Viglianti, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2024-203822

Published: 2024

Journal Articles

Ras Activity Is Significantly Elevated in Patients with Primary Myelofibrosis and Is Agnostic to the Presence of RAS and JAK pathwaymutations

Samuel B Reynolds, Malathi Kandarpa, Kristen Marie Pettit, Mark Ribick, Moshe Talpaz, Qing Li

Blood (2023) 142 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2023-179503

Published: 2023

Journal Articles

Clinical Features and Outcomes of Patients with Myelofibrosis and RAS Pathway Activating Mutations at the University of Michigan

Lisa P. Chu, Malathi Kandarpa, Dan Robinson, Yi-Mi Wu, Moshe Talpaz, Kristen M. Pettit

Blood (2021) 138 (Supplement 1): 4643.

https://doi.org/10.1182/blood-2021-149159

Published: 2021

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Malathi Kandarpa, PhD, Kristen Pettit, MD, Yi-Mi Wu, PhD, Qing Li, MD, Robert Lonigro, Dan Robinson, PhD, Luke F. Peterson, PhD, Philip S Boonstra, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2018) 132 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2018-99-113418

Published: 2018

Journal Articles

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Benjamin Garmezy, MD, Philip S Boonstra, PhD, Malathi Kandarpa, PhD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 2929.

https://doi.org/10.1182/blood.V130.Suppl_1.2929.2929

Published: 2017

Journal Articles

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann, Stephen M. Courtney, Matthew Young, Hollis D. Showalter, Duxin Sun, Andrzej Jakubowiak, Sami N. Malek, Moshe Talpaz, Nicholas J. Donato

Blood (2015) 125 (23): 3588–3597.

https://doi.org/10.1182/blood-2014-10-605584

Published: 2015

Includes: Supplemental data

Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2127.

https://doi.org/10.1182/blood.V124.21.2127.2127

Published: 2014

Journal Articles

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Martin van Vliet, PhD, Jagoda Jasielec, MD, Dominik Dytfeld, MD PhD, Ravi Vij, MD, Belinda Dumee, BSc, Lizanne Bosman, BSc, Leonie C.M. deBest, MSc, Mattina Alonge, MS, Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Kathryn McDonnell, BS, Kent A. Griffith, Erik H van Beers, PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2141.

https://doi.org/10.1182/blood.V124.21.2141.2141

Published: 2014

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Mattina M. Alonge, Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 279.

https://doi.org/10.1182/blood.V122.21.279.279

Published: 2013

NARROW

Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Examining Ras/MAP Kinase Signaling in Primary Myelofibrosis May Yield Insight into the Mechanisms of JAK Inhibitor Resistance and Provide New Therapeutic Targets

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Ras Activity Is Significantly Elevated in Patients with Primary Myelofibrosis and Is Agnostic to the Presence of RAS and JAK pathwaymutations

Clinical Features and Outcomes of Patients with Myelofibrosis and RAS Pathway Activating Mutations at the University of Michigan

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only